First thing's first: Don't tell everyone. Jonathan Kitchen/Getty Images

If you have a successful tech startup, you may be working towards an exit plan where your vision and innovation is turned into liquidity. When a unique, innovative idea hits the big time, investors and other tech companies take notice, and some founders of startups discover themselves with sudden wealth.

Whether you take your company public or are eventually acquired by a much larger organization, you may find yourself looking at millions or billions of dollars one day. If this happens to you, there are crucial steps you should consider to help ensure you stay financially healthy for the long-term.

Keep your head down and do your homework.

First, be as quiet as possible about your new windfall. While selling your company may be public knowledge, keep conversations about your finances and situation minimal and confidential until you have a plan. The more hushed you keep your new financial situation, the less pressure you may have from others asking for favors and handouts.

Additionally, do your research before making any decisions. While you are coming to terms with your new wealth, search for the right team, including a financial adviser, attorney, and accountant, to help you set your goals, both long and short term. This may include tax efficiency and structure, such as trusts and family limited partnerships.

Research a potential advisers' philosophy, fees, and expertise. Have a background check run on anyone you hire, including their financial situation. Review your engagement letter and understand the small print. Be patient as you search for the right team — they are extremely important to your future.

Find an adviser you trust.

Part of your team should include a financial adviser who can be an invaluable resource during this time and into the future for many reasons.

First, he or she can help you identify potential present and future financial goals, plan for the next generation, and structure an income stream, which will ultimately help guide your money to survive you. You might find yourself in the unique position to make donations you have only dreamed of, and that, too, requires guidance.

A financial adviser can also help when friends and organizations are looking for financial contributions from you. Sudden wealth often leads to many changes which are hard to anticipate. Do not let your guard down. Family and friends can come out of the woodwork. Also, be aware of frivolous lawsuits and threats. Keep you and your family safe.

Don't go crazy.

Be disciplined in your spending. Some pro-athletes and lottery winners have filed for bankruptcy after blowing all of their wealth. Do not fall into this trap.

With the help of your financial adviser, you may decide to put your money where you cannot access it easily, such as a house or a 529 savings plan for your children's college. Or, you may decide to have your financial adviser help establish a salary for you each month so you can control your cash better.

After working hard to build a product or platform and the success of selling it for top dollar, ensure you are just as wise with your proceeds. Follow trusted advice from a well-vetted financial adviser and take your time to make major decisions. Trust your gut and enjoy the ride!

------

Gail Stalarow is vice president and financial adviser with The Clarity Group in the Wealth Management Division of Morgan Stanley in Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”